PhoreMost Ltd
Building B580, Room 2011
Babraham Research Campus
Babraham
Cambridge
CB22 3AT
United Kingdom
Tel: 44-0-1223-804-163
Website: http://www.phoremost.com/
Email: info@phoremost.com
26 articles with PhoreMost Ltd
-
BioSpace Global Roundup: June 27
6/27/2019
Biotech and pharma companies from across the globe share pipeline and business updates. -
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
6/12/2019
Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.
-
PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs
6/21/2018
The collaboration will see o2h deploy its expertise in medicinal chemistry to help progress PhoreMost’s portfolio rapidly through the hit-to-lead and lead-optimisation stages of drug discovery.
-
PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company
11/15/2017
Sixth Element Capital LLP announces a £3 million investment in NeoPhore, a spin out from Cambridge, UK based PhoreMost Ltd
-
PhoreMost Ltd And University of Cambridge Collaborate To Identify Innovative Drug Targets For Neurodegenerative Disease
10/12/2016
-
PhoreMost Ltd And The Wistar Institute Collaborate To Identify New Druggable Targets In Cancer, Immunotherapy And Aging
3/10/2016